Sugi Predict

Sugi Predict / Compounds / SCHEMBL7893733

SCHEMBL7893733

SCHEMBL7893733

Nc1nc2ccc(Br)cc2o1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CG P48736 1/20 0.61
▸ MAPT P10636 6/20 0.47
▸ LMNA P02545 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ BACE1 P56817 2/20 0.46
▸ PABPC1 P11940 1/20 0.44
▸ LCK P06239 1/20 0.41
▸ KDM4E B2RXH2 4/20 0.41
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ HPGD P15428 2/20 0.41
▸ GLA P06280 1/20 0.41
▸ GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30988526 1.00 PIK3CG (0.61) PIK3CGMAPTLMNACYP1A2THRB
SCHEMBL7897748 0.84 MAPT (0.61) PIK3CGMAPTLMNACYP1A2THRB
SCHEMBL4390043 0.79 PIK3CG (0.66) PIK3CGMAPTLMNACYP1A2THRB
SCHEMBL10950114 0.79 PIK3CG (0.66) PIK3CGMAPTLMNACYP1A2THRB
SCHEMBL353596 0.76 POLB (0.48) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL21983971 0.76 PIK3CG (0.61) PIK3CGMAPTLMNACYP1A2THRB
SCHEMBL15582914 0.76 PIK3CG (0.61) PIK3CGMAPTLMNACYP1A2THRB
SCHEMBL20552113 0.76 PIK3CG (0.43) PIK3CGMAPTCYP1A2BACE1PABPC1
SCHEMBL20552452 0.76 DAGLA (0.39) PIK3CGMAPTCYP1A2BACE1PABPC1
SCHEMBL9896463 0.76 PIK3CG (1.00) PIK3CGMAPTLMNACYP1A2THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4105216-B1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GENFLEET THERAPEUTICS SHANGHAI INC (CN) 2026-05-20 — — EP disclosed
EP-4727938-A1 BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2026-04-22 — — EP disclosed
EP-3653626-B1 NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME DAEWOONG PHARMACEUTICAL CO LTD (KR) 2025-09-17 — — EP disclosed
WO-2024259121-A1 BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2024-12-19 — — WO disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 — — US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 — — US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 — — US disclosed
CN-118324706-A Benzoxazole derivative and application thereof 贵州省天然产物研究中心 2024-07-12 — — CN disclosed
EP-4387965-A2 ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS ChemoCentryx, Inc. (US) 2024-06-26 — — EP disclosed
US-12012403-B2 Aryl sulfonyl compounds as CCR6 inhibitors CHEMOCENTRYX, INC. (US) 2024-06-18 — — US disclosed
US-20120294930-A1 COMBINATION OF KINASE INHIBITORS AND USES THEREOF INTELLIKINE LLC (US) 2012-11-22 — — US disclosed
US-20120294930-A1 COMBINATION OF KINASE INHIBITORS AND USES THEREOF INTELLIKINE LLC (US) 2012-11-22 — — US disclosed
WO-2012151562-A1 COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF INTELLIKINE, LLC (US) 2012-11-08 — — WO disclosed
WO-2012148540-A1 COMBINATION OF KANASE INHIBITORS AND USES THREOF INTELLIKINE, LLC (US) 2012-11-01 — — WO disclosed
US-20100190749-A1 Benzoxazole kinase inhibitors and methods of use FAETH THERAPEUTICS, INC. 2010-07-29 — — US disclosed
US-20100190749-A1 Benzoxazole kinase inhibitors and methods of use FAETH THERAPEUTICS, INC. 2010-07-29 — — US disclosed
US-20100184760-A1 Benzoxazole kinase inhibitors and methods of use FAETH THERAPEUTICS, INC. 2010-07-22 — — US disclosed
US-20100184760-A1 Benzoxazole kinase inhibitors and methods of use FAETH THERAPEUTICS, INC. 2010-07-22 — — US disclosed
WO-2010051043-A1 BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE, INC. (US) 2010-05-06 — — WO disclosed
WO-2010051042-A1 BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE, INC. (US) 2010-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 KLK5, KLK1, KLKB1 PIK3CG 1357/4885MAPT 1734/4885LMNA 1466/4885
US-20100184760-A1 Benzoxazole kinase inhibitors and methods of use BMX, MTOR, PDPK1 PIK3CG 23/4885MAPT 3161/4885LMNA 3015/4885
US-12012403-B2 Aryl sulfonyl compounds as CCR6 inhibitors CCR6, CCR1, CCR3 PIK3CG 4695/4885MAPT 3747/4885LMNA 4517/4885
US-20100190749-A1 Benzoxazole kinase inhibitors and methods of use BMX, MTOR, PDPK1 PIK3CG 23/4885MAPT 3161/4885LMNA 3015/4885
US-20120294930-A1 COMBINATION OF KINASE INHIBITORS AND USES THEREOF MTOR, AKT2, MTMR1 PIK3CG 50/4885MAPT 1588/4885LMNA 2872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.